Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan to Require Pledges from Troubled Generic Makers to Skip Next Listing Round If Supply Issues Occur Again
The Ministry of Health, Labor and Welfare (MHLW) will introduce a new measure to ensure stable generic supplies, beginning with the upcoming December listing. Generic makers that had supply problems for products listed in the previous two listing rounds will…
To read the full story
Related Article
- Written Pledge Rule on Generic Listing to Continue after 2021; Companies Feel Pressure for Stable Supplies
December 7, 2021
- MHLW to Tighten “Written Pledge” Rule on Generic Listings to Thwart Supply Issues
July 26, 2021
- MHLW Plans to Introduce Scheme to Scrutinize Generic Makers’ Stable Supply Ability, Beginning with December Listing
June 18, 2020
REGULATORY
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
- MHLW Unveils Preventive Healthcare Plan Focused on Dementia, Other Areas
July 24, 2026
- MHLW Eyes Limited Charge Exemptions for OTC-Like Topical Drugs
July 24, 2026
- MHLW Panel Voices Disappointment over Efluelda Launch Delay
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…